Your browser doesn't support javascript.
loading
Discovering High Potent Hsp90 Inhibitors as Antinasopharyngeal Carcinoma Agents through Fragment Assembling Approach.
Xu, Mengyang; Zhao, Chao; Zhu, Biying; Wang, Liangyue; Zhou, Huihao; Yan, Daoguang; Gu, Qiong; Xu, Jun.
Afiliação
  • Xu M; Research Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
  • Zhao C; Department of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China.
  • Zhu B; Research Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
  • Wang L; Shenzhen Cell Inspire Therapeutics Co., Ltd., Shenzhen 518101, China.
  • Zhou H; Department of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China.
  • Yan D; Research Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
  • Gu Q; Research Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
  • Xu J; Department of Biotechnology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China.
J Med Chem ; 64(4): 2010-2023, 2021 02 25.
Article em En | MEDLINE | ID: mdl-33543615
ABSTRACT
Hsp90 is a new promising target for cancer treatment. Many inhibitors have been discovered as therapeutic agents, and some have passed Phase I and II. However, no one is approved by FDA yet. Novel and druggable Hsp90 inhibitors are still demanding. Here, we report a new way to discover high potent Hsp90 inhibitors as antinasopharyngeal carcinoma agents through assembling fragments. With chemotyping analysis, we extract seven chemotypes from 3482 known Hsp90 inhibitors, screen 500 fragments that are compatible with the chemotypes, and confirm 15 anti-Hsp90 fragments. Click chemistry is employed to construct 172 molecules and synthesize 21 compounds among them. The best inhibitor 3d was further optimized and resulted in more potent 4f (IC50 = 0.16 µM). In vitro and in vivo experiments confirmed that 4f is a promising agent against nasopharyngeal carcinoma. This study may provide a strategy in discovering new ligands against targets without well-understood structures.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Triazóis / Neoplasias Nasofaríngeas / Proteínas de Choque Térmico HSP90 / Carcinoma Nasofaríngeo / Antineoplásicos Limite: Animals / Humans / Male Idioma: En Revista: J Med Chem Assunto da revista: QUIMICA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Triazóis / Neoplasias Nasofaríngeas / Proteínas de Choque Térmico HSP90 / Carcinoma Nasofaríngeo / Antineoplásicos Limite: Animals / Humans / Male Idioma: En Revista: J Med Chem Assunto da revista: QUIMICA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China